Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-13 pm EST			5-day change	1st Jan Change
55.36 ^USD	-0.84%		-2.33%	-2.12%

07:58am	Lannebo Sverige Plus increased 1.5 percent in December - holdings in SEB, Essity and Swedbank reduced	FW
Jan. 13	Lannebo Sweden increased 0.5 percent in December - global license agreement for BioArctic	FW

Bristol Myers: positive opinion for repotrectinib in U

November 15, 2024 at 07:36 am EST

Bristol Myers Squibb announces that it has received a positive opinion from the CHMP of the European Medicines Agency for its repotrectinib in the treatment of ROS1-positive advanced non-small cell lung cancer and NTRK-positive advanced solid tumors.

This recommendation is based on data from the TRIDENT-1 and CARE registration trials, which demonstrated robust responses and durable activity with repotrectinib in these two indications, in adults and over 12s respectively.

The European Commission, which has the power to approve drugs for the European Union, will now review the CHMP (Committee for Medicinal Products for Human Use) recommendation, with its final decision expected in January 2025.

'If approved, repotrectinib has the potential to be a best-in-class treatment for patients with ROS1-positive non-small cell lung cancer in the European Union', Bristol Myers points out.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about Bristol-Myers Squibb Company

Lannebo Sverige Plus increased 1.5 percent in December - holdings in SEB, Essity and Swedbank reduced	01:58am	FW
Lannebo Sweden increased 0.5 percent in December - global license agreement for BioArctic	Jan. 13	FW
Bristol-Myers Squibb Company Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 07:30 AM	Jan. 13
Bristol-Myers Squibb Company Exercises Exclusive License Option for ArsenalBio's AB-4000 Series	Jan. 13	MT
Annexon, Inc. Appoints William ?BJ? Jones to Its Board of Directors	Jan. 10	CI
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $52 From $53, Maintains Neutral Rating	Jan. 10	MT
Truist Raises Price Target on Bristol-Myers Squibb to $65 From $62, Keeps Buy Rating	Jan. 08	MT
Bristol Myers Squibb Announces FDA Approval of Cobenfy	Jan. 08	CI
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Jan. 03	MT
Lexicon Pharmaceuticals, Inc. Appoints Scott M. Coiante as Senior Vice President	Jan. 02	CI
Lexicon Pharmaceuticals, Inc. Announces CFO Changes	Jan. 02	CI
European Equities Close Mostly Higher in Tuesday Trading; EU Withholds Over $1 Billion From Hungary	Dec. 31	MT
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Dec. 31	MT
Bristol Myers: Opdivo Qvantig approved for subcutaneous use	Dec. 30	CF
US FDA Clears Injectable Form of Bristol Myers Squibb's Cancer Medication	Dec. 29	MT
Bristol Myers Squibb Receives FDA Approval for Cancer Treatment	Dec. 27	DJ
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig?? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications	Dec. 27	CI
Bristol-Myers Squibb's Opdivo Qvantig Gets US FDA Approval	Dec. 27	MT
Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis	Dec. 23	DJ
Bristol-Myers Squibb Says Phase 3 Trials of Sotyktu in Psoriatic Arthritis Meets Endpoints	Dec. 23	MT
Bristol Myers: positive data in psoriatic arthritis	Dec. 23	CF
Bristol-Myers Squibb Secures EU Approval for Opdivo, Yervoy Combination in Colorectal Cancer	Dec. 23	MT
Bristol Myers Squibb: received EU approval	Dec. 23	CF
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis	Dec. 23	CI
Bristol Myers Squibb Receives European Commission Approval for Opdivo® Plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer	Dec. 23	CI

Chart Bristol-Myers Squibb Company

Duration

Period

BMY: Dynamic Chart

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Employees

34,100

Sector

Pharmaceuticals

Calendar

2025-02-06 - Q4 2024 Earnings Release

More about the company